Overall Status

Terminated (2)

Active, not recruiting (1)

Completed (1)

Phase

phase 1 (3)

phase 2 (1)

Sponsor

ARCAGY/ GINECO GROUP (1)

AstraZeneca (1)

Novartis Pharmaceuticals (1)

Pamela Munster (1)

Collaborator

QuantumLeap Healthcare Collaborative (1)

Intervention

paclitaxel (3)

carboplatin (2)

bevacizumab (1)

bkm120 (1)

bmn-673 (1)

capecitabine (1)

ku-0059436 (azd2281)(parp inhibitor) (1)

lde225 (1)

paclitaxel + carboplatin (1)

Study Documents

Intervention Type

drug (4)

Funder Type

Industry (2)

Other (2)

Study Type

Interventional (4)

triple negative metastatic breast cancer

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin Trial in Belgium, Netherlands, United Kingdom

Active, not recruiting

Triple Negative Metastatic Breast Cancer
+3 more

KU-0059436 (AZD2281)(PARP inhibitor)
+3 more

Brussels, Belgium
+3 more

Dec 19, 2022

Dose Escalation, Safety, Preliminary Efficacy Trial in Worldwide (LDE225, BKM120)

Completed

Dose Escalation
+11 more

Los Angeles, California
+22 more

Dec 16, 2020

Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor Trial in San Francisco (BMN-673, Carboplatin, Paclitaxel)

Terminated

Triple Negative Metastatic Breast Cancer
BRCA-mutated Solid Tumor

BMN-673
+2 more

San Francisco, California

University of California San Francisco

Jan 7, 2020

Triple Negative Metastatic Breast Cancer Trial in France (Paclitaxel, Bevacizumab, Capecitabine)

Terminated

Triple Negative Metastatic Breast Cancer

Paclitaxel
+2 more

Angers, France
+16 more

Mar 15, 2016